S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q3 2025

Baker Bros Advisors

Period: Q3 2025 Β· Filed: 2025-11-14
View on SEC EDGAR β†—
AUM
$13.84B
Total portfolio value
Positions
91
Reported securities
Top Holding
ONC
21.7% $3.00B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2025-11-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ONCBeOne Medicines Ltd.$3.00B21.66%$340.70$297.65-12.6%
21.7%
INCYIncyte Corporation$2.61B18.84%$84.81$116.86+37.8%
18.8%
MDGLMadrigal Pharmaceuticals, Inc.$982.3M7.10%$458.66$528.10+15.1%
7.1%
INSMInsmed Incorporated$965.4M6.98%$144.01$111.60-22.5%
7.0%
ACADACADIA Pharmaceuticals Inc.$915.4M6.61%$21.34$25.97+21.7%
6.6%
SMMTSummit Therapeutics Inc.$696.7M5.03%$20.66$15.42-25.4%
5.0%
RYTMRhythm Pharmaceuticals, Inc.$566.0M4.09%$100.99$114.17+13.1%
4.1%
RVMDRevolution Medicines, Inc.$441.6M3.19%$46.70$189.24+305.2%
3.2%
CELCCelcuity Inc.$391.0M2.83%$49.40$107.95+118.5%
2.8%
KYMRKymera Therapeutics, Inc.$376.5M2.72%$56.60$113.51+100.5%
2.7%
KODKodiak Sciences Inc.$283.4M2.05%$16.37$38.54+135.4%
2.0%
ALKSAlkermes plc$242.7M1.75%$30.00$54.58+81.9%
1.8%
ABCLAbCellera Biologics Inc.$138.4M1.00%$5.03$8.11+61.2%
1.0%
EWTXEdgewise Therapeutics, Inc.$118.5M0.86%$16.22$39.56+143.9%
0.9%
KNSAKiniksa Pharmaceuticals International, plc$109.7M0.79%$38.83$64.53+66.2%
0.8%
STOKStoke Therapeutics, Inc.$108.9M0.79%$23.50$32.70+39.1%
0.8%
IMTXImmatics N.V.$103.0M0.74%$8.52$9.95+16.8%
0.7%
GRALGRAIL, Inc.$96.4M0.70%$59.13$69.11+16.9%
0.7%
IDYAIDEAYA Biosciences, Inc.$89.1M0.64%$27.21$37.65+38.4%
0.6%
IMVTImmunovant, Inc.$88.0M0.64%$16.12$38.79+140.6%
0.6%
IMCRImmunocore Holdings plc$84.4M0.61%$36.33$32.50-10.5%
0.6%
BCYCBicycle Therapeutics plc$84.3M0.61%$7.74$4.35-43.8%
0.6%
RAREUltragenyx Pharmaceutical Inc.$83.4M0.60%$30.08$33.47+11.3%
0.6%
ABVXAbivax S.A.$74.4M0.54%$84.90$144.65+70.4%
0.5%
ARWRArrowhead Pharmaceuticals, Inc.$57.6M0.42%$34.49$83.99+143.5%
0.4%
ROIVRoivant Sciences Ltd.$57.0M0.41%$15.13$35.13+132.2%
0.4%
DNLIDenali Therapeutics Inc.$54.2M0.39%$14.52$25.83+77.9%
0.4%
MRUSMerus N.V.$54.1M0.39%β€”β€”
0.4%
NTLAIntellia Therapeutics, Inc.$47.4M0.34%$17.27$17.56+1.7%
0.3%
REPLReplimune Group, Inc.$46.3M0.33%$4.19$11.58+176.4%
0.3%

Quarter-on-Quarter Activity

Q3 2025 vs. Q2 2025

New Positions (8)

TickerIssuerNotionalSince Filing
ABVXAbivax S.A.$74.4M+70.4%
Celcuity Inc.$40.9M
IONSIonis Pharmaceuticals, Inc.$37.1M
RNAMAvidity Biosciences, Inc.$27.2M
VKTXViking Therapeutics, Inc.$9.6M
PHVSPharvaris N.V.$9.4M
HRTXHeron Therapeutics, Inc.$5.4M
MBXMBX Biosciences, Inc.$4.9M

Exited Positions (8)

TickerIssuerNotional
VRNAVerona Pharma plc$21.2M
VERVVerve Therapeutics, Inc.$19.0M
BPMCBlueprint Medicines Corporation$16.1M
IGMSIGM Biosciences, Inc.$4.6M
FATEFate Therapeutics, Inc.$2.8M
CADLCandel Therapeutics, Inc.$1.8M
RCKTRocket Pharmaceuticals, Inc.$1.4M
HOOKHOOKIPA Pharma Inc.$1.0M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
RAPPRapport Therapeutics, Inc.$39.7M+181.2%
ARWRArrowhead Pharmaceuticals, Inc.$42.8M+77.9%+143.5%
XNCRXencor, Inc.$7.7M+64.4%
SYRESpyre Therapeutics, Inc.$7.4M+59.6%
IDYAIDEAYA Biosciences, Inc.$44.6M+54.6%+38.4%
VTVTvTv Therapeutics, Inc.$2.0M+52.4%
CELCCelcuity Inc.$318.3M+45.2%+118.5%
ALKSAlkermes plc$59.3M+26.2%+81.9%

Trimmed (5)

TickerIssuerNotionalShares Ξ”Since Filing
CTNMContineum Therapeutics, Inc.$-0.3M-75.1%
GPCRStructure Therapeutics Inc.$-8.5M-38.0%
CERSCerus Corporation$-2.3M-22.3%
KALAKALA BIO, Inc.$-4.2M-18.0%
INSMInsmed Incorporated$189.1M-13.1%-22.5%
← Back to Hedge Funds